ROCKVILLE, Md., July 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Gregory Glenn, M.D., as the company's Chief Scientific Officer who will report to Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. Previously, Dr.

GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ -- Iomai Corporation announced that its Chief Scientific Officer, Gregory Glenn, M.D., and Alexander Von Gabain, Ph.

GAITHERSBURG, Md. and VIENNA, Austria, June 11 /PRNewswire-FirstCall/ -- Iomai Corporation today announced the publication of data from the company's positive Phase II field study of its travelers' diarrhea vaccine in The Lancet.

GAITHERSBURG, Md., April 8, 2008 /PRNewswire-FirstCall/ -- Iomai Corporation today announced it will receive a cost-reimbursement grant for up to $943,856 from the U.S. Army Medical Research and Materiel Command (USAMRMC) to perform preclinical work on a patch-based version of the anthrax vaccine.

GAITHERSBURG, Md., April 3, 2008 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that it has signed an agreement with Merck & Co., Inc. to conduct proof-of-principle preclinical studies evaluating the use of the Iomai needle-free immunostimulant patch.